% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Korshunov:143049,
      author       = {A. Korshunov$^*$ and B. Casalini$^*$ and L. Chavez$^*$ and
                      T. Hielscher$^*$ and M. Sill$^*$ and M. Ryzhova and T.
                      Sharma$^*$ and D. Schrimpf$^*$ and D. Stichel$^*$ and D.
                      Capper$^*$ and D. E. Reuss$^*$ and D. Sturm$^*$ and O.
                      Absalyamova and A. Golanov and S. Lambo$^*$ and M.
                      Bewerunge-Hudler$^*$ and P. Lichter$^*$ and C. Herold-Mende
                      and W. Wick$^*$ and S. Pfister$^*$ and M. Kool$^*$ and D.
                      Jones$^*$ and A. von Deimling$^*$ and F. Sahm$^*$},
      title        = {{I}ntegrated molecular characterization of {IDH}-mutant
                      glioblastomas.},
      journal      = {Neuropathology $\&$ applied neurobiology},
      volume       = {45},
      number       = {2},
      issn         = {0305-1846},
      address      = {Oxford [u.a.]},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2019-00668},
      pages        = {108 - 118},
      year         = {2019},
      abstract     = {Mutations of isocitrate dehydrogenase (IDH)1/2 affect
                      almost all astrocytomas of WHO grade II and III. A subset of
                      IDH-mutant astrocytic tumours progresses to IDH-mutant
                      glioblastoma or presents with the histology of a
                      glioblastoma at first presentation. We set out here to
                      assess the molecular spectrum of IDH-mutant glioblastomas.We
                      performed an integrated molecular analysis of a mono-centric
                      cohort (n = 97); assessed through genome-wide DNA
                      methylation analysis, copy-number profiling and targeted
                      next generation sequencing using a neurooncology-tailored
                      gene panel.Of these 97 IDH-mutant glioblastomas, 68 had a
                      glioblastoma at first presentation (de novo IDH-mutant
                      glioblastoma) and 29 emerged from a prior low-grade lesion
                      (evolved IDH-mutant glioblastoma). Unsupervised hierarchical
                      clustering of DNA methylation data disclosed that IDH-mutant
                      glioblastoma (de novo and evolved) formed a distinct group
                      separate from other diffuse glioma subtypes. Homozygous
                      deletions of CDKN2A/B were found to be associated with
                      shorter survival.This study demonstrates DNA methylation
                      patterns in IDH-mutant glioblastoma to be distinct from
                      lower-grade astrocytic counterparts but homogeneous within
                      de novo and evolved IDH-mutant glioblastomas, and identifies
                      CDKN2A as a marker for possible genetic sub-stratification.},
      cin          = {B300 / B062 / C060 / W110 / B060 / B320 / L101 / L201},
      ddc          = {610},
      cid          = {I:(DE-He78)B300-20160331 / I:(DE-He78)B062-20160331 /
                      I:(DE-He78)C060-20160331 / I:(DE-He78)W110-20160331 /
                      I:(DE-He78)B060-20160331 / I:(DE-He78)B320-20160331 /
                      I:(DE-He78)L101-20160331 / I:(DE-He78)L201-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30326163},
      doi          = {10.1111/nan.12523},
      url          = {https://inrepo02.dkfz.de/record/143049},
}